Home
Home

tafamidis

The Meaningless Drug Approval That Could Cost the Industry Billions

The Meaningless Drug Approval That Could Cost the Industry Billions
Motley Fool

FDA Panel Sends Mixed Message About Pfizer Drug

FDA Panel Sends Mixed Message About Pfizer Drug
Pharmalot

Pfizer, FoldRx drug extends survival

Pfizer, FoldRx drug extends survival
Fierce Biotech

Pfizer receives 'refuse to file' letter from FDA for compound tafamidis

Pfizer receives 'refuse to file' letter from FDA for compound tafamidis
Yahoo/AP

News

FoldRx banks $29M for neurodegenerative drug application
Fierce Biotech
»